drugset
drugset / Trial / NCT05038020

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

NCT05038020 ↗

Phase 2 Terminated 3 enrolled Alkahest, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).

Timeline

Start
2021-08-17
Primary completion
2021-12-09
Completion
2022-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject LAZUCIRNON Small molecule 400 mg Oral

Indications

diabetic retinopathy